Ucf-101|cas:313649-08-0|西域试剂

Ucf-101,98.33%

产品编号：Bellancom-125959| CAS NO：313649-08-0| 分子式：C₂₇H₁₇N₃O₅S| 分子量：495.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-125959	￥1000.00	杭州北京（现货）
Bellancom-125959	￥1700.00	杭州北京（现货）
Bellancom-125959	￥3500.00	杭州北京（现货）
Bellancom-125959	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ucf-101

产品介绍

Ucf-101 是一种选择性和竞争性的促凋亡蛋白酶 Omi/HtrA2 抑制剂，抑制 His-Omi 的 IC₅₀ 值为 9.5 μM。Ucf-101 对各种其他丝氨酸蛋白酶的活性极低 (IC₅₀>200 μM)。Ucf-101 在 543 nm 处具有天然的红色荧光，可用于监视其进入哺乳动物细胞的能力。Ucf-101 对 MI/R 损伤具有明显的心脏保护作用，并且还具有一定的神经保护作用。

生物活性

Ucf-101 is a selective and competitive inhibitor of pro-apoptotic protease Omi/HtrA2, with an IC₅₀ of 9.5 μM for His-Omi. Ucf-101 exhibits very little activity against various other serine proteases (IC₅₀>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect.

体外研究

Ucf-101 (20-100 μM; 30 min) inhibits the proteolytic activity of MBP-Omi-(134-458).
Ucf-101 (10-100 μM; pretreated for 10 min) inhibits His-Omi-(134-458) activity in a concentration-dependent manner when assayed with His-Omi-(134-458) and β-casein.
Ucf-101 (1-25 μM; 36 h) inhibits Omi-induced caspase-independent apoptosis of mouse embryo caspase-9 (-/-) null fibroblasts.
Ucf-101 (1-20 μM; pretreated for 1 h) inhibits the 6-OHDA-induced apoptosis of Parkinson’s disease (PD)-PC12 cells at the low concentration (2.5 μM), and increases the apoptosis rate at the high concentration (≥10 μM).
Ucf-101 (2.5 μM; pretreated for 1 h) downregulates the expression of Glucose-regulated protein 78 (Bip/Grp78) and C/EBP homologous protein (CHOP) in PD- PC12 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Ucf-101 (0.6-1.8 μmol/kg; a single i.p.) reduces postischemic myocardial apoptosis and myocardial infarct size in mice.
Ucf-101 (1.5 μmol/kg; a single i.p.) improves the APO-induced rotational behavior, increases the TH-positive cells and reverses the reduction of DA neurons in the PD rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male mice (20-25 g) with myocardial ischemia/reperfusion (MI/R) injury
Dosage:	0.6, 1.5, 1.8 μmol/kg
Administration:	I.p. 10 minutes before reperfusion
Result:	Reduced terminal dUTP nick end-labeling staining, incidence of DNA ladder fragmentation, and infarct size.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male mice (20-25 g) with myocardial ischemia/reperfusion (MI/R) injury
Dosage:	0.6, 1.5, 1.8 μmol/kg
Administration:	I.p. 10 minutes before reperfusion
Result:	Reduced terminal dUTP nick end-labeling staining, incidence of DNA ladder fragmentation, and infarct size.

性状

Solid

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (25.23 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0181 mL	10.0906 mL	20.1812 mL
5 mM	0.4036 mL	2.0181 mL	4.0362 mL
10 mM	0.2018 mL	1.0091 mL	2.0181 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1.79 mg/mL (3.61 mM); Suspended solution; Need ultrasonic

此方案可获得 1.79 mg/mL (3.61 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 17.9 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.67 mg/mL (3.37 mM); Suspended solution; Need ultrasonic

此方案可获得 1.67 mg/mL (3.37 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液